Biotech | November 20, 2021
Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
Nelarabine is in a class of medications called antimetabolites
Platina 250, 300 & 350 Lamitubes have been recognized by the Association of Plastic Recyclers (APR), USA as meeting or exceeding the strict APR HDPE critical guidance criteria on recyclability
Two out of three people under the age of 40 are at risk of prediabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Vakrangee’s distribution network across rural India will help penetrate underserved markets
The group now has 324 approvals and has so far filed over 400 ANDAs
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
Subscribe To Our Newsletter & Stay Updated
